GlyNAC supplies glycine and N-acetylcysteine (a cysteine donor), the two rate-limiting precursors for glutathione (GSH) synthesis, correcting the age-related glutathione deficiency documented in older adults. Restoring intracellular GSH reduces oxidative stress and improves mitochondrial fatty-acid oxidation, addressing hallmark aging processes tied to redox imbalance and mitochondrial dysfunction. In published human RCTs, 16-week GlyNAC supplementation in older adults corrected glutathione deficiency and oxidative stress, improved mitochondrial function, insulin resistance, physical function (walking speed), and cognition versus controls; a larger multi-dose RCT confirmed the redox and oxidative-stress effects. Evidence to date is functional and biomarker-based — GlyNAC does not yet have published mortality or morbidity outcome data, unlike hard-endpoint interventions such as GLP-1 agonists or SGLT2 inhibitors.
GlyNAC — the combination of glycine and N-acetylcysteine (NAC) — is sold as a dietary supplement combination. It is not FDA-approved as a drug for any indication, including longevity.
Two RCTs from the same Baylor College of Medicine research group (Kumar 2021, n=8 older adults vs. young controls; a 2023 extension, n=45) found GlyNAC supplementation corrected age-related glutathione deficiency and improved oxidative stress, mitochondrial function, inflammation, insulin resistance, and physical function. A larger 2022 multi-dose RCT (n=114, Frontiers in Aging) confirmed the redox and oxidative-stress effects.
The available trials are small, come primarily from one research group, and measure surrogate/functional endpoints — glutathione levels, oxidative stress markers, physical function — rather than hard outcomes like mortality or morbidity. Independent replication in larger trials is the key evidence gap.
No. The 2021 Kumar trial found that glutathione levels and downstream markers reversed to pre-treatment baseline within 12 weeks of stopping GlyNAC. Any observed benefit appears to require continuous supplementation, not a one-time correction.
GlyNAC supplies both rate-limiting precursors for glutathione synthesis — glycine and cysteine (via NAC) — rather than NAC alone. Trials specifically evaluating GlyNAC as a combination are what Geroevidence tracks for this profile; NAC monotherapy has a separate and larger literature base outside the aging/longevity context.